AstraZeneca's Datroway boosts survival in advanced breast cancer trial
06/10/2025 07:55
Oct 6 (Reuters) - AstraZeneca AZN.L said on Monday its precision drug Datroway improved overall survival and progression free survival in patients with an advanced form of breast cancer versus chemotherapy in a trial when given early during treatment. The treatment, which is being developed with partner Daiichi Sankyo 4568.T, was given as first-line therapy in the trial for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option, AstraZeneca said. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Nivedita Bhattacharjee) ((pushkala.a@thomsonreuters.com; X and LinkedIn: @pullthekart;))